{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:46:00Z","timestamp":1777985160478,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.farma.2025.03.004","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T05:25:50Z","timestamp":1742707550000},"page":"T99-T108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Consensus on intraocular drug preparations"],"prefix":"10.1016","volume":"49","author":[{"given":"Gonzaga","family":"Garay-Aramburu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Alonso Herreros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"N\u00fa\u00f1ez Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"M\u00e1rquez Peir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"V\u00e1zquez Cruchaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gonz\u00e1lez del Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ignacio","family":"Fern\u00e1ndez-Vigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.farma.2025.03.004_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000486145","article-title":"2018 Update on Intravitreal Injections: Euretina expert consensus recommendations","volume":"239","author":"Grzybowski","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.farma.2025.03.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","volume":"80","author":"Melo","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"10.1016\/j.farma.2025.03.004_bb0015","unstructured":"Armad\u00e1 Maresca F. Castro Balado A. Patolog\u00eda Retiniana y el Uso de Antiangiog\u00e9nicos en la Actualidad. En: Gonz\u00e1lez del Valle F., Ya\u00f1ez Mart\u00ednez J., Alonso Herreros J.M.,Coordinadores. Diez temas candentes en oftalmolog\u00eda y farmacia hospitalaria, 2021, Sociedad Espa\u00f1ola de Farmacia Hospitalaria, Sociedad Espa\u00f1ola de Oftalmolog\u00eda; Madrid. p. 36-42."},{"key":"10.1016\/j.farma.2025.03.004_bb0020","series-title":"Segunda revisi\u00f3n. Gu\u00edas de Pr\u00e1ctica Cl\u00ednica y Monograf\u00edas de la SERV [Monograf\u00eda en Internet]","article-title":"Manejo de las inyecciones intrav\u00edtreas","author":"G\u00f3mez-Ulla","year":"2018"},{"issue":"2","key":"10.1016\/j.farma.2025.03.004_bb0025","first-page":"82","article-title":"Consenso SEO-SEFH sobre recomendaciones de utilizaci\u00f3n y elaboraci\u00f3n de preparaciones oft\u00e1lmicas","volume":"42","author":"Fuentes-Irigoyen","year":"2018","journal-title":"Farm Hosp"},{"key":"10.1016\/j.farma.2025.03.004_bb0030","author":"Ficha t\u00e9cnica de Lucentis\u00ae jeringa precargada"},{"key":"10.1016\/j.farma.2025.03.004_bb0035","author":"Ficha t\u00e9cnica de Eylea\u00ae jeringa precargada"},{"key":"10.1016\/j.farma.2025.03.004_bb0040","author":"Ficha t\u00e9cnica de Beovu\u00ae jeringa precargada"},{"issue":"5","key":"10.1016\/j.farma.2025.03.004_bb0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3928\/23258160-20190503-05","article-title":"Inflammatory reaction after aflibercept intravitreal injections associated with silicone oil droplets released from syringes: a case-control study","volume":"50","author":"Melo","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina."},{"issue":"4","key":"10.1016\/j.farma.2025.03.004_bb0050","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/1120672118823133","article-title":"Silicone oil droplets in repackaged anti-vascular endothelial growth factors for intravitreal injections: in search of the main source of contamination","volume":"30","author":"Olea","year":"2020","journal-title":"Eur J Ophthalmol."},{"issue":"11","key":"10.1016\/j.farma.2025.03.004_bb0055","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaophthalmol.2023.4326","article-title":"Presumed silicone oil droplets after intravitreal pegcetacoplan injections","volume":"141","author":"Dessouki","year":"2023","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous."},{"key":"10.1016\/j.farma.2025.03.004_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-018-0153-8","article-title":"Release of silicone oil droplets from syringes","volume":"5","author":"Melo","year":"2019","journal-title":"Int J Retina Vitreous."},{"key":"10.1016\/j.farma.2025.03.004_bb0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/OPTH.S207978","article-title":"Issues with intravitreal administration of Anti-VEGF Drugs","volume":"14","author":"Schargus","year":"2020","journal-title":"Clin Ophthalmol."},{"issue":"2","key":"10.1016\/j.farma.2025.03.004_bb0075","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"2","key":"10.1016\/j.farma.2025.03.004_bb0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bjophthalmol-2019-313823","article-title":"Release of silicone oil and the off-label use of syringes in Ophthalmology","volume":"104","author":"Melo","year":"2019","journal-title":"Br J Ophthalmol."},{"key":"10.1016\/j.farma.2025.03.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","volume":"80","author":"Melo","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"10.1016\/j.farma.2025.03.004_bb0090","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.xphs.2016.04.015","article-title":"Aggregation and particle formation of therapeutic proteins in contact with a novel fluoropolymer surface versus siliconized surfaces: effects of agitation in vials and in prefilled syringes","volume":"105","author":"Teska","year":"2016","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.farma.2025.03.004_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jps.24184","article-title":"Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins","volume":"104","author":"Krayukhina","year":"2015","journal-title":"J Pharm Sci."},{"issue":"6","key":"10.1016\/j.farma.2025.03.004_bb0100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41433-019-0365-7","article-title":"Needles as a source of silicone oil during intravitreal injection","volume":"33","author":"Melo","year":"2019","journal-title":"Eye (Lond)."},{"issue":"4","key":"10.1016\/j.farma.2025.03.004_bb0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000002947","article-title":"Particulate matter from syringes used for intravitreal injections","volume":"41","author":"Dounce","year":"2021","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.farma.2025.03.004_bb0110","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaophthalmol.2023.4326","article-title":"Presumed silicone oil droplets after intravitreal pegcetacoplan injections","volume":"141","author":"Dessouki","year":"2023","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"10.1016\/j.farma.2025.03.004_bb0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/ICB.0000000000000570","article-title":"Large silicone droplets after intravitreal bevacizumab (Avastin)","volume":"13","author":"Avery","year":"2019","journal-title":"Retin Cases Brief Rep."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40942-023-00507-3","article-title":"Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties","volume":"9","author":"J\u00f8rstad","year":"2023","journal-title":"Int J Retina Vitreous."},{"key":"10.1016\/j.farma.2025.03.004_bb0125","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.3389\/fopht.2022.882013","article-title":"A silicone oil-free syringe tailored for intravitreal injection of biologics","volume":"2","author":"Gj\u00f8lberg","year":"2022","journal-title":"Front Ophthalmol."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0130","doi-asserted-by":"crossref","first-page":"18021","DOI":"10.1038\/s41598-019-54226-7","article-title":"A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes","volume":"9","author":"Lode","year":"2019","journal-title":"Sci Rep."},{"issue":"7","key":"10.1016\/j.farma.2025.03.004_bb0135","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.oret.2023.06.003","article-title":"Accuracy, precision, and residual volume of commonly used syringes for intravitreal injections and the impact on intraocular pressure","volume":"10","author":"Agra","year":"2023","journal-title":"Ophthalmol Retina."},{"key":"10.1016\/j.farma.2025.03.004_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119704","article-title":"Do not flick or drop off-label use plastic syringes in handling therapeutic proteins before administration","volume":"587","author":"Kim","year":"2020","journal-title":"Int J Pharm."},{"key":"10.1016\/j.farma.2025.03.004_bb0145","author":"Reglamento (UE) 2017\/745 del Parlamento Europeo y del Consejo de 5 de abril de 2017 sobre los productos sanitarios. Diario Oficial de la Uni\u00f3n Europea (5 de abril de 2017)"},{"key":"10.1016\/j.farma.2025.03.004_bb0150","unstructured":"Real Decreto 192\/2023, de 21 de marzo, por el que se regulan los productos sanitarios. Bolet\u00edn Oficial del Estado, n\u00b0 69, (21 de marzo de 2023). [Consultado 01 Oct 2024]. Disponible en: https:\/\/www.boe.es\/eli\/es\/rd\/2023\/03\/21\/192\/dof\/spa\/pdf"},{"key":"10.1016\/j.farma.2025.03.004_bb0155","author":"Asociaci\u00f3n Espa\u00f1ola de Normalizaci\u00f3n, UNE. Agujas hipod\u00e9rmicas est\u00e9riles de un solo uso Requisitos y m\u00e9todos de ensayo"},{"key":"10.1016\/j.farma.2025.03.004_bb0160","author":"Congruence Medical Solution LLC. Baltimore (USA)"},{"key":"10.1016\/j.farma.2025.03.004_bb0165","author":"SJJ Solutions B.V. La Haya (Netherland)"},{"key":"10.1016\/j.farma.2025.03.004_bb0170","author":"FCI S.A.S. \u2013 France Chirurgie Instrumentation. Paris (Francia)"},{"key":"10.1016\/j.farma.2025.03.004_bb0175","author":"Andersen Caledonia Co. North Lanarkshire (Scotland)"},{"key":"10.1016\/j.farma.2025.03.004_bb0180","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.2147\/OPTH.S309501","article-title":"Comparison of two different intravitreal injection techniques","volume":"15","author":"Uy","year":"2021","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.farma.2025.03.004_bb0215","author":"Krader"},{"key":"10.1016\/j.farma.2025.03.004_bb0185","author":"FDA (USA). Staclear\u00ae information"},{"key":"10.1016\/j.farma.2025.03.004_bb0190","author":"FDA (USA).Ocusafe\u00ae FDA information"},{"key":"10.1016\/j.farma.2025.03.004_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100862","article-title":"Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections","volume":"80","author":"Melo","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"10.1016\/j.farma.2025.03.004_bb0200","author":"Resolution CM\/ResAP (2011)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. Council of Europe"},{"key":"10.1016\/j.farma.2025.03.004_bb0205","article-title":"Gu\u00eda de buenas pr\u00e1cticas de preparaci\u00f3n de medicamentos en los servicios de Farmacia Hospitalaria. Ministerio de Sanidad, Servicios Sociales e Igualdad","author":"MSSSI","year":"2014","journal-title":"Junio"},{"key":"10.1016\/j.farma.2025.03.004_bb0210","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaophthalmol.2018.7089","article-title":"The argument for sterile loading of all intravitreal injections and the benefit of replicated results","volume":"137","author":"VanderBeek","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.farma.2025.03.004_bb0220","author":"Ficha t\u00e9cnica Lucentis\u00ae"},{"key":"10.1016\/j.farma.2025.03.004_bb0225","author":"Ficha t\u00e9cnica Eylea\u00ae"},{"key":"10.1016\/j.farma.2025.03.004_bb0230","author":"Ficha t\u00e9cnica Faricimab\u00ae"},{"key":"10.1016\/j.farma.2025.03.004_bb0235","author":"Real Decreto Ley 16\/2012 de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones"},{"key":"10.1016\/j.farma.2025.03.004_bb0240","author":"Malmstrom"},{"key":"10.1016\/j.farma.2025.03.004_bb0245","series-title":"Practical stability studies of therapeutic proteins in oncology [Monograf\u00eda en internet]","author":"Astier","year":"2012"},{"key":"10.1016\/j.farma.2025.03.004_bb0270","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/eye.2015.28","article-title":"Storage stability of bevacizumab in polycarbonate and polypropylene syringes","volume":"39","author":"Khalili","year":"2015","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.farma.2025.03.004_bb0275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jcjo.2016.11.012","article-title":"Long-term in vitro functional stability of compounded ranibizumab and aflibercept","volume":"52","author":"Cao","year":"2017","journal-title":"Can J Ophthalmol."},{"key":"10.1016\/j.farma.2025.03.004_bb0280","author":"Roche"},{"key":"10.1016\/j.farma.2025.03.004_bb0285","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40942-023-00507-3","article-title":"Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties","volume":"9","author":"J\u00f8rstad","year":"2023","journal-title":"Int J Retin Vitr."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9394(14)73272-6","article-title":"Stability of recombinant tissue plasminogen activator","volume":"108","author":"Jaffe","year":"1989","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ejhpharm-2013-000307","article-title":"Development of ready-to-use cefuroxime syringes for use in ophthalmology","volume":"21","author":"Fleury-Souverain","year":"2014","journal-title":"Eur J Hosp Pharm Sci Pract."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0300","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/03639045.2015.1038273","article-title":"Stability of 10 mg\/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method","volume":"42","author":"Feutry","year":"2016","journal-title":"Drug Dev Ind Pharm."},{"issue":"7","key":"10.1016\/j.farma.2025.03.004_bb0305","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/IAE.0b013e31820039af","article-title":"Long-term potency, sterility, and stability of vancomycin, ceftazidime, and moxifloxacin for treatment of bacterial endophthalmitis","volume":"31","author":"Mehta","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.farma.2025.03.004_bb0310","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.1995.tb00705.x","article-title":"Stability of vancomycin in plastic syringes measured by high-performance liquid chromatography","volume":"20","author":"Wood","year":"1995","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.farma.2025.03.004_bb0315","first-page":"109","article-title":"Stability of clindamycin phosphate in dextrose and saline solutions","volume":"42","author":"Das Gupta","year":"1989","journal-title":"Can J Hosp Pharm."},{"issue":"2","key":"10.1016\/j.farma.2025.03.004_bb0320","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1078155217732629","article-title":"Long-term stability of ganciclovir in polypropylene containers at room temperature","volume":"25","author":"Guichard","year":"2019","journal-title":"J Oncol Pharm Pract."},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0325","first-page":"88","article-title":"Stability of foscarnet sodium in 0.9% sodium chloride injection","volume":"51","author":"Woods","year":"1994","journal-title":"Am J Hosp Pharm."},{"issue":"5","key":"10.1016\/j.farma.2025.03.004_bb0330","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1590\/S1413-86702008000500011","article-title":"Treatment of invasive fungal infections: stability of voriconazole infusion solutions in PVC bags","volume":"12","author":"Adams","year":"2008","journal-title":"Braz J Infect Dis."},{"key":"10.1016\/j.farma.2025.03.004_bb0335","series-title":"Compounding guide for ophthalmic preparations","first-page":"205","author":"McElhiney","year":"2013"},{"issue":"4","key":"10.1016\/j.farma.2025.03.004_bb0340","first-page":"261","article-title":"Dexamethasone phosphate stability and contamination of solutions stored in syringes","volume":"50","author":"Lau","year":"1996","journal-title":"PDA J Pharm Sci Technol."},{"key":"10.1016\/j.farma.2025.03.004_bb0345","first-page":"395","article-title":"Chemical stability of dexamethasone sodium phosphate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes","volume":"6","author":"Gupta","year":"2002","journal-title":"Int J Pharm Compound."},{"key":"10.1016\/j.farma.2025.03.004_bb0350","series-title":"Compounding guide for ophthalmic preparations","first-page":"236","author":"McElhiney","year":"2013"},{"key":"10.1016\/j.farma.2025.03.004_bb0355","unstructured":"Grupo de Farmacotecnia de la SEFH. Procedimientos normalizados de elaboraci\u00f3n (PN). Madrid: Sociedad Espa\u00f1ola de Farmacia Hospitalaria. [Consultado 01 Oct 2024]. Disponible en: https:\/\/gruposdetrabajo.sefh.es\/farmacotecnia\/index.php\/formulas-magistrales."},{"key":"10.1016\/j.farma.2025.03.004_bb0360","unstructured":"Alonso Herreros J.M., Preparaci\u00f3n de medicamentos y formulaci\u00f3n magistral para oftalmolog\u00eda, 2003, Ediciones D\u00edaz de Santos; Madrid. p. 13-131."},{"key":"10.1016\/j.farma.2025.03.004_bb0365","series-title":"Formulaci\u00f3n Magistral Oft\u00e1lmica Antiinfecciosa","author":"Fern\u00e1ndez","year":"2019"},{"issue":"2","key":"10.1016\/j.farma.2025.03.004_bb0250","first-page":"5","volume":"4","author":"D\u00e1vila Pousa","year":"2014","journal-title":"Bolet\u00edn Informativo Farmacotecnia del Grupo de Trabajo de Farmacotecnia de la SEFH"},{"key":"10.1016\/j.farma.2025.03.004_bb0255","series-title":"Acreditaci\u00f3n y formaci\u00f3n continuada de manipuladores de salas blancas. Monograf\u00edas de Farmacia Hospitalaria: Centralizaci\u00f3n de la elaboraci\u00f3n de medicamentos en los servicios de farmacia hospitalaria","first-page":"34","volume":"n\u00b0 18","author":"Alonso Herreros","year":"2022"},{"key":"10.1016\/j.farma.2025.03.004_bb0260","author":"PiC\/S guide to good practices for the preparation of medicinal products in health-care establishments PE 010-4"},{"issue":"1","key":"10.1016\/j.farma.2025.03.004_bb0265","article-title":"Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: a systematic review and meta-analysis","volume":"7","author":"Bande","year":"2017","journal-title":"Sci Rep Sci Rep."}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:11:02Z","timestamp":1750137062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1130634325000224"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.03.004","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Consensus on intraocular drug preparations","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.11.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}